A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

NCT04346888 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Myasthenia Gravis

Interventions

DRUG: HBM9161 Injection (680mg and 340 mg)
DRUG: Placebos
DRUG: HBM9161 Injection (340 mg)

Sponsor

Harbour BioMed (Guangzhou) Co. Ltd.